Share Price and Basic Stock Data
Last Updated: January 24, 2026, 4:34 pm
| PEG Ratio | 2.99 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Procter & Gamble Health Ltd operates in the pharmaceuticals sector, showcasing robust performance metrics. As of the latest reporting, the company’s stock price stood at ₹5,411, with a market capitalization of ₹8,989 Cr. The trailing twelve months (TTM) sales amounted to ₹1,284 Cr, reflecting a significant revenue growth trajectory from ₹1,114 Cr in June 2022 to ₹1,230 Cr by June 2023. Quarterly sales figures indicate stability, with the most recent quarter (September 2023) reporting sales of ₹305 Cr. Over the past year, the company has demonstrated resilience despite market fluctuations, maintaining a sales range between ₹252 Cr and ₹339 Cr in the subsequent quarters. This performance underscores P&G Health’s ability to navigate a competitive landscape while capitalizing on its strong brand equity and product offerings.
Profitability and Efficiency Metrics
P&G Health’s profitability metrics reveal a well-managed cost structure and strong operational efficiency. The company recorded a net profit of ₹307 Cr, translating to a net profit margin of 25.09% for the year ending March 2025. Operating profit margins (OPM) have shown fluctuation, with the latest figure at 37% for the most recent quarter. The interest coverage ratio (ICR) stood remarkably high at 764.51x, indicating that the company operates with minimal debt, as evidenced by borrowings of just ₹6 Cr. Return on equity (ROE) was reported at 36.4%, showcasing effective utilization of shareholder equity, while return on capital employed (ROCE) reached 47.8%, reflecting robust operational profitability. These metrics highlight P&G Health’s operational strengths and its ability to generate significant returns on invested capital, positioning it favorably within the pharmaceuticals sector.
Balance Sheet Strength and Financial Ratios
The balance sheet of Procter & Gamble Health Ltd reflects a solid financial foundation, characterized by low leverage and healthy liquidity. The company reported total reserves of ₹603 Cr, with borrowings held at a minimal ₹6 Cr, highlighting its conservative approach to debt management. The current ratio stood at 2.44, indicating strong short-term liquidity, while the quick ratio of 1.94 further supports this assertion. Additionally, the price-to-book value (P/BV) ratio was recorded at 15.90x, suggesting that investors are willing to pay a premium for the company’s shares relative to its book value. This premium pricing may indicate strong market confidence in its future earnings potential. However, the high P/BV ratio also suggests that the stock could be overvalued compared to typical sector ranges, warranting cautious evaluation by potential investors.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Procter & Gamble Health Ltd indicates a stable ownership structure, with promoters holding 51.82% of the equity. Foreign institutional investors (FIIs) accounted for 7.24%, while domestic institutional investors (DIIs) held 13.90%. Public ownership stood at 27.05%, with the number of shareholders declining to 50,006, down from 63,831 in December 2022. This trend may suggest a consolidation of shares among larger investors, potentially enhancing the stability of the stock. The consistent promoter holding reflects confidence in the company’s long-term growth potential. However, fluctuations in institutional investments can be indicative of market sentiment and confidence. The relatively low FII presence could also suggest a lower foreign interest in the stock, which may impact liquidity and trading volumes.
Outlook, Risks, and Final Insight
Looking ahead, Procter & Gamble Health Ltd faces both opportunities and challenges. The company’s strong profitability metrics and low debt levels provide a solid foundation for future growth, particularly as it navigates potential market expansions and product innovations. However, risks include the potential for fluctuating raw material costs and regulatory changes impacting the pharmaceuticals sector, which could affect margins. Additionally, the high P/BV ratio raises concerns about valuation sustainability. Investors should remain vigilant regarding external market conditions and consumer demand trends. Should the company successfully leverage its brand strength and maintain operational efficiencies, it could continue to enhance shareholder value. Conversely, any adverse regulatory changes or competitive pressures could pose challenges to its growth trajectory.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 126 Cr. | 99.9 | 197/84.3 | 27.8 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,463 Cr. | 318 | 479/192 | 71.7 | 24.3 | 0.21 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.6 Cr. | 43.9 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 61.0 Cr. | 41.7 | 43.4/17.0 | 145 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,525.73 Cr | 1,087.19 | 47.43 | 202.32 | 0.38% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 298 | 310 | 321 | 301 | 305 | 310 | 252 | 284 | 313 | 310 | 311 | 339 | 325 |
| Expenses | 207 | 201 | 241 | 256 | 216 | 208 | 185 | 236 | 199 | 186 | 230 | 248 | 205 |
| Operating Profit | 91 | 109 | 80 | 45 | 89 | 102 | 67 | 48 | 114 | 123 | 81 | 90 | 120 |
| OPM % | 31% | 35% | 25% | 15% | 29% | 33% | 27% | 17% | 36% | 40% | 26% | 27% | 37% |
| Other Income | 3 | 5 | 5 | 5 | 6 | 5 | 2 | -18 | 3 | 4 | 3 | 4 | 5 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 7 | 8 | 6 | 6 | 6 | 7 | 7 | 7 | 6 | 6 | 5 | 5 | 6 |
| Profit before tax | 87 | 105 | 79 | 44 | 88 | 100 | 63 | 23 | 111 | 122 | 79 | 89 | 119 |
| Tax % | 26% | 27% | 25% | 32% | 26% | 28% | 26% | 26% | 26% | 25% | 22% | 25% | 26% |
| Net Profit | 64 | 77 | 59 | 30 | 66 | 72 | 47 | 17 | 82 | 91 | 61 | 66 | 89 |
| EPS in Rs | 38.35 | 46.27 | 35.66 | 17.96 | 39.50 | 43.42 | 28.05 | 10.11 | 49.60 | 54.76 | 36.86 | 39.87 | 53.34 |
Last Updated: December 29, 2025, 12:05 pm
Below is a detailed analysis of the quarterly data for Procter & Gamble Health Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 325.00 Cr.. The value appears to be declining and may need further review. It has decreased from 339.00 Cr. (Jun 2025) to 325.00 Cr., marking a decrease of 14.00 Cr..
- For Expenses, as of Sep 2025, the value is 205.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 248.00 Cr. (Jun 2025) to 205.00 Cr., marking a decrease of 43.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 120.00 Cr.. The value appears strong and on an upward trend. It has increased from 90.00 Cr. (Jun 2025) to 120.00 Cr., marking an increase of 30.00 Cr..
- For OPM %, as of Sep 2025, the value is 37.00%. The value appears strong and on an upward trend. It has increased from 27.00% (Jun 2025) to 37.00%, marking an increase of 10.00%.
- For Other Income, as of Sep 2025, the value is 5.00 Cr.. The value appears strong and on an upward trend. It has increased from 4.00 Cr. (Jun 2025) to 5.00 Cr., marking an increase of 1.00 Cr..
- For Interest, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00 Cr..
- For Depreciation, as of Sep 2025, the value is 6.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 5.00 Cr. (Jun 2025) to 6.00 Cr., marking an increase of 1.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 119.00 Cr.. The value appears strong and on an upward trend. It has increased from 89.00 Cr. (Jun 2025) to 119.00 Cr., marking an increase of 30.00 Cr..
- For Tax %, as of Sep 2025, the value is 26.00%. The value appears to be increasing, which may not be favorable. It has increased from 25.00% (Jun 2025) to 26.00%, marking an increase of 1.00%.
- For Net Profit, as of Sep 2025, the value is 89.00 Cr.. The value appears strong and on an upward trend. It has increased from 66.00 Cr. (Jun 2025) to 89.00 Cr., marking an increase of 23.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 53.34. The value appears strong and on an upward trend. It has increased from 39.87 (Jun 2025) to 53.34, marking an increase of 13.47.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:47 am
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Jun 2020n n 18m | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025n n 16m | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 867 | 940 | 993 | 698 | 849 | 927 | 1,356 | 1,009 | 1,114 | 1,230 | 1,151 | 934 | 1,284 |
| Expenses | 809 | 855 | 877 | 621 | 701 | 723 | 1,037 | 762 | 846 | 905 | 845 | 616 | 869 |
| Operating Profit | 59 | 85 | 116 | 77 | 148 | 204 | 319 | 246 | 268 | 325 | 307 | 319 | 415 |
| OPM % | 7% | 9% | 12% | 11% | 17% | 22% | 24% | 24% | 24% | 26% | 27% | 34% | 32% |
| Other Income | 20 | 22 | 24 | 74 | 768 | 48 | 66 | 18 | 13 | 18 | -5 | 10 | 16 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 1 |
| Depreciation | 13 | 23 | 25 | 19 | 21 | 17 | 29 | 30 | 27 | 28 | 27 | 17 | 22 |
| Profit before tax | 67 | 83 | 115 | 132 | 895 | 234 | 355 | 233 | 253 | 314 | 273 | 312 | 408 |
| Tax % | 35% | 36% | 31% | 29% | 6% | 32% | 28% | 24% | 24% | 27% | 26% | 25% | |
| Net Profit | 43 | 54 | 79 | 94 | 839 | 159 | 254 | 177 | 193 | 229 | 201 | 234 | 307 |
| EPS in Rs | 26.04 | 32.27 | 47.67 | 56.57 | 505.27 | 95.64 | 153.07 | 106.51 | 115.98 | 138.24 | 121.08 | 141.22 | 184.83 |
| Dividend Payout % | 23% | 23% | 23% | 27% | 87% | 0% | 150% | 122% | 45% | 69% | 215% | 89% |
YoY Net Profit Growth
| Year |
|---|
| YoY Net Profit Growth (%) |
| Change in YoY Net Profit Growth (%) |
No data available for trend analysis.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 1% |
| 5 Years: | 0% |
| 3 Years: | -3% |
| TTM: | 11% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 8% |
| 3 Years: | 10% |
| TTM: | 43% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 24% |
| 5 Years: | 6% |
| 3 Years: | 14% |
| 1 Year: | 24% |
| Return on Equity | |
|---|---|
| 10 Years: | 28% |
| 5 Years: | 27% |
| 3 Years: | 33% |
| Last Year: | 36% |
Last Updated: September 5, 2025, 12:40 pm
Balance Sheet
Last Updated: December 4, 2025, 1:50 am
| Month | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 |
| Reserves | 538 | 575 | 647 | 717 | 1,524 | 800 | 890 | 687 | 600 | 734 | 522 | 520 | 603 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 3 | 12 | 10 | 8 | 6 |
| Other Liabilities | 154 | 192 | 215 | 258 | 219 | 250 | 269 | 275 | 269 | 338 | 247 | 250 | 268 |
| Total Liabilities | 708 | 784 | 879 | 991 | 1,759 | 1,067 | 1,176 | 986 | 888 | 1,101 | 794 | 794 | 894 |
| Fixed Assets | 110 | 132 | 111 | 115 | 104 | 101 | 101 | 104 | 112 | 144 | 128 | 116 | 106 |
| CWIP | 28 | 7 | 30 | 9 | 17 | 11 | 21 | 39 | 41 | 32 | 6 | 11 | 13 |
| Investments | 24 | 42 | 28 | 70 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 547 | 603 | 711 | 797 | 1,639 | 954 | 1,053 | 843 | 736 | 925 | 660 | 667 | 776 |
| Total Assets | 708 | 784 | 879 | 991 | 1,759 | 1,067 | 1,176 | 986 | 888 | 1,101 | 794 | 794 | 894 |
Below is a detailed analysis of the balance sheet data for Procter & Gamble Health Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 17.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 17.00 Cr..
- For Reserves, as of Sep 2025, the value is 603.00 Cr.. The value appears strong and on an upward trend. It has increased from 520.00 Cr. (Mar 2025) to 603.00 Cr., marking an increase of 83.00 Cr..
- For Borrowings, as of Sep 2025, the value is 6.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 8.00 Cr. (Mar 2025) to 6.00 Cr., marking a decrease of 2.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 268.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 250.00 Cr. (Mar 2025) to 268.00 Cr., marking an increase of 18.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 894.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 794.00 Cr. (Mar 2025) to 894.00 Cr., marking an increase of 100.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 106.00 Cr.. The value appears to be declining and may need further review. It has decreased from 116.00 Cr. (Mar 2025) to 106.00 Cr., marking a decrease of 10.00 Cr..
- For CWIP, as of Sep 2025, the value is 13.00 Cr.. The value appears strong and on an upward trend. It has increased from 11.00 Cr. (Mar 2025) to 13.00 Cr., marking an increase of 2.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 776.00 Cr.. The value appears strong and on an upward trend. It has increased from 667.00 Cr. (Mar 2025) to 776.00 Cr., marking an increase of 109.00 Cr..
- For Total Assets, as of Sep 2025, the value is 894.00 Cr.. The value appears strong and on an upward trend. It has increased from 794.00 Cr. (Mar 2025) to 894.00 Cr., marking an increase of 100.00 Cr..
Notably, the Reserves (603.00 Cr.) exceed the Borrowings (6.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Jun 2020n n 18m | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025n n 16m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 59.00 | 85.00 | 116.00 | 77.00 | 148.00 | 204.00 | 319.00 | 238.00 | 265.00 | 313.00 | 297.00 | 319.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 44 | 49 | 39 | 64 | 28 | 30 | 26 | 22 | 27 | 34 | 27 | 57 |
| Inventory Days | 162 | 140 | 145 | 243 | 154 | 139 | 113 | 138 | 124 | 136 | 120 | 152 |
| Days Payable | 40 | 55 | 67 | 128 | 124 | 106 | 105 | 209 | 185 | 239 | 184 | 239 |
| Cash Conversion Cycle | 166 | 134 | 118 | 179 | 58 | 63 | 34 | -49 | -34 | -69 | -37 | -30 |
| Working Capital Days | 74 | 69 | 52 | 94 | 42 | 22 | 23 | 7 | 17 | 15 | 19 | 48 |
| ROCE % | 12% | 15% | 18% | 16% | 78% | 20% | 29% | 29% | 38% | 45% | 45% | 48% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Nippon India Small Cap Fund | 692,659 | 0.58 | 395.02 | 596,807 | 2025-12-08 07:42:13 | 16.06% |
| ICICI Prudential Smallcap Fund | 362,766 | 2.45 | 206.89 | 360,975 | 2026-01-26 08:54:41 | 0.5% |
| UTI MNC Fund | 229,559 | 4.58 | 130.92 | 240,895 | 2025-12-14 02:16:25 | -4.71% |
| DSP Healthcare Fund | 159,288 | 2.92 | 90.84 | 158,704 | 2025-12-07 19:34:14 | 0.37% |
| ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund | 71,471 | 0.63 | 40.76 | N/A | N/A | N/A |
| Aditya Birla Sun Life MNC Fund | 69,716 | 1.11 | 39.76 | N/A | N/A | N/A |
| UTI Healthcare Fund | 66,803 | 3.46 | 38.1 | 67,014 | 2026-01-25 11:07:48 | -0.31% |
| ICICI Prudential Bharat Consumption Fund | 22,192 | 0.39 | 12.66 | 22,442 | 2026-01-25 11:07:48 | -1.11% |
| Aditya Birla Sun Life Pharma & Healthcare Fund | 19,000 | 1.29 | 10.84 | N/A | N/A | N/A |
| UTI Balance Advantage Fund | 15,271 | 0.27 | 8.71 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 141.00 | 133.00 | 138.00 | 116.00 | 107.00 |
| Diluted EPS (Rs.) | 141.00 | 121.00 | 138.00 | 116.00 | 107.00 |
| Cash EPS (Rs.) | 151.26 | 137.58 | 155.16 | 132.29 | 124.60 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 323.47 | 324.24 | 452.34 | 371.38 | 423.92 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 323.47 | 324.24 | 452.34 | 371.38 | 423.92 |
| Dividend / Share (Rs.) | 125.00 | 260.00 | 95.00 | 52.50 | 130.00 |
| Revenue From Operations / Share (Rs.) | 562.75 | 693.53 | 740.73 | 671.33 | 607.67 |
| PBDIT / Share (Rs.) | 198.04 | 193.75 | 206.67 | 169.20 | 159.11 |
| PBIT / Share (Rs.) | 187.98 | 177.25 | 189.74 | 152.88 | 141.01 |
| PBT / Share (Rs.) | 187.72 | 164.65 | 189.28 | 152.63 | 140.53 |
| Net Profit / Share (Rs.) | 141.21 | 121.07 | 138.23 | 115.97 | 106.51 |
| PBDIT Margin (%) | 35.19 | 27.93 | 27.90 | 25.20 | 26.18 |
| PBIT Margin (%) | 33.40 | 25.55 | 25.61 | 22.77 | 23.20 |
| PBT Margin (%) | 33.35 | 23.74 | 25.55 | 22.73 | 23.12 |
| Net Profit Margin (%) | 25.09 | 17.45 | 18.66 | 17.27 | 17.52 |
| Return on Networth / Equity (%) | 43.65 | 37.34 | 30.55 | 31.22 | 25.12 |
| Return on Capital Employeed (%) | 53.90 | 51.13 | 39.50 | 38.57 | 31.32 |
| Return On Assets (%) | 29.51 | 25.30 | 20.83 | 21.54 | 17.92 |
| Asset Turnover Ratio (%) | 1.18 | 1.21 | 1.23 | 1.19 | 0.93 |
| Current Ratio (X) | 2.44 | 2.39 | 2.62 | 2.60 | 3.04 |
| Quick Ratio (X) | 1.94 | 1.90 | 2.18 | 2.11 | 2.55 |
| Inventory Turnover Ratio (X) | 8.55 | 2.38 | 2.55 | 2.77 | 2.29 |
| Dividend Payout Ratio (NP) (%) | 99.14 | 206.48 | 40.87 | 147.43 | 215.93 |
| Dividend Payout Ratio (CP) (%) | 92.55 | 181.71 | 36.41 | 129.25 | 184.57 |
| Earning Retention Ratio (%) | 0.86 | -106.48 | 59.13 | -47.43 | -115.93 |
| Cash Earning Retention Ratio (%) | 7.45 | -81.71 | 63.59 | -29.25 | -84.57 |
| Interest Coverage Ratio (X) | 764.51 | 446.71 | 445.55 | 668.74 | 330.15 |
| Interest Coverage Ratio (Post Tax) (X) | 546.14 | 308.18 | 299.01 | 459.38 | 222.00 |
| Enterprise Value (Cr.) | 8347.67 | 8138.39 | 8273.45 | 6626.39 | 8817.13 |
| EV / Net Operating Revenue (X) | 8.94 | 7.07 | 6.73 | 5.95 | 8.74 |
| EV / EBITDA (X) | 25.39 | 25.30 | 24.12 | 23.59 | 33.38 |
| MarketCap / Net Operating Revenue (X) | 9.14 | 7.28 | 7.09 | 6.24 | 9.21 |
| Retention Ratios (%) | 0.85 | -106.48 | 59.12 | -47.43 | -115.93 |
| Price / BV (X) | 15.90 | 15.57 | 11.60 | 11.28 | 13.20 |
| Price / Net Operating Revenue (X) | 9.14 | 7.28 | 7.09 | 6.24 | 9.21 |
| EarningsYield | 0.02 | 0.02 | 0.02 | 0.02 | 0.01 |
After reviewing the key financial ratios for Procter & Gamble Health Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 141.00. This value is within the healthy range. It has increased from 133.00 (Mar 24) to 141.00, marking an increase of 8.00.
- For Diluted EPS (Rs.), as of Mar 25, the value is 141.00. This value is within the healthy range. It has increased from 121.00 (Mar 24) to 141.00, marking an increase of 20.00.
- For Cash EPS (Rs.), as of Mar 25, the value is 151.26. This value is within the healthy range. It has increased from 137.58 (Mar 24) to 151.26, marking an increase of 13.68.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 323.47. It has decreased from 324.24 (Mar 24) to 323.47, marking a decrease of 0.77.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 323.47. It has decreased from 324.24 (Mar 24) to 323.47, marking a decrease of 0.77.
- For Dividend / Share (Rs.), as of Mar 25, the value is 125.00. This value exceeds the healthy maximum of 3. It has decreased from 260.00 (Mar 24) to 125.00, marking a decrease of 135.00.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 562.75. It has decreased from 693.53 (Mar 24) to 562.75, marking a decrease of 130.78.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 198.04. This value is within the healthy range. It has increased from 193.75 (Mar 24) to 198.04, marking an increase of 4.29.
- For PBIT / Share (Rs.), as of Mar 25, the value is 187.98. This value is within the healthy range. It has increased from 177.25 (Mar 24) to 187.98, marking an increase of 10.73.
- For PBT / Share (Rs.), as of Mar 25, the value is 187.72. This value is within the healthy range. It has increased from 164.65 (Mar 24) to 187.72, marking an increase of 23.07.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 141.21. This value is within the healthy range. It has increased from 121.07 (Mar 24) to 141.21, marking an increase of 20.14.
- For PBDIT Margin (%), as of Mar 25, the value is 35.19. This value is within the healthy range. It has increased from 27.93 (Mar 24) to 35.19, marking an increase of 7.26.
- For PBIT Margin (%), as of Mar 25, the value is 33.40. This value exceeds the healthy maximum of 20. It has increased from 25.55 (Mar 24) to 33.40, marking an increase of 7.85.
- For PBT Margin (%), as of Mar 25, the value is 33.35. This value is within the healthy range. It has increased from 23.74 (Mar 24) to 33.35, marking an increase of 9.61.
- For Net Profit Margin (%), as of Mar 25, the value is 25.09. This value exceeds the healthy maximum of 10. It has increased from 17.45 (Mar 24) to 25.09, marking an increase of 7.64.
- For Return on Networth / Equity (%), as of Mar 25, the value is 43.65. This value is within the healthy range. It has increased from 37.34 (Mar 24) to 43.65, marking an increase of 6.31.
- For Return on Capital Employeed (%), as of Mar 25, the value is 53.90. This value is within the healthy range. It has increased from 51.13 (Mar 24) to 53.90, marking an increase of 2.77.
- For Return On Assets (%), as of Mar 25, the value is 29.51. This value is within the healthy range. It has increased from 25.30 (Mar 24) to 29.51, marking an increase of 4.21.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.18. It has decreased from 1.21 (Mar 24) to 1.18, marking a decrease of 0.03.
- For Current Ratio (X), as of Mar 25, the value is 2.44. This value is within the healthy range. It has increased from 2.39 (Mar 24) to 2.44, marking an increase of 0.05.
- For Quick Ratio (X), as of Mar 25, the value is 1.94. This value is within the healthy range. It has increased from 1.90 (Mar 24) to 1.94, marking an increase of 0.04.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 8.55. This value exceeds the healthy maximum of 8. It has increased from 2.38 (Mar 24) to 8.55, marking an increase of 6.17.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 99.14. This value exceeds the healthy maximum of 50. It has decreased from 206.48 (Mar 24) to 99.14, marking a decrease of 107.34.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 92.55. This value exceeds the healthy maximum of 50. It has decreased from 181.71 (Mar 24) to 92.55, marking a decrease of 89.16.
- For Earning Retention Ratio (%), as of Mar 25, the value is 0.86. This value is below the healthy minimum of 40. It has increased from -106.48 (Mar 24) to 0.86, marking an increase of 107.34.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 7.45. This value is below the healthy minimum of 40. It has increased from -81.71 (Mar 24) to 7.45, marking an increase of 89.16.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 764.51. This value is within the healthy range. It has increased from 446.71 (Mar 24) to 764.51, marking an increase of 317.80.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 546.14. This value is within the healthy range. It has increased from 308.18 (Mar 24) to 546.14, marking an increase of 237.96.
- For Enterprise Value (Cr.), as of Mar 25, the value is 8,347.67. It has increased from 8,138.39 (Mar 24) to 8,347.67, marking an increase of 209.28.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 8.94. This value exceeds the healthy maximum of 3. It has increased from 7.07 (Mar 24) to 8.94, marking an increase of 1.87.
- For EV / EBITDA (X), as of Mar 25, the value is 25.39. This value exceeds the healthy maximum of 15. It has increased from 25.30 (Mar 24) to 25.39, marking an increase of 0.09.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 9.14. This value exceeds the healthy maximum of 3. It has increased from 7.28 (Mar 24) to 9.14, marking an increase of 1.86.
- For Retention Ratios (%), as of Mar 25, the value is 0.85. This value is below the healthy minimum of 30. It has increased from -106.48 (Mar 24) to 0.85, marking an increase of 107.33.
- For Price / BV (X), as of Mar 25, the value is 15.90. This value exceeds the healthy maximum of 3. It has increased from 15.57 (Mar 24) to 15.90, marking an increase of 0.33.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 9.14. This value exceeds the healthy maximum of 3. It has increased from 7.28 (Mar 24) to 9.14, marking an increase of 1.86.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Procter & Gamble Health Ltd:
- Net Profit Margin: 25.09%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 53.9% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 43.65% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 546.14
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.94
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 29.2 (Industry average Stock P/E: 47.43)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 25.09%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | P&G Plaza, Cardinal Gracias Road, Mumbai Maharashtra 400009 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. S Madhavan | Chairman & Ind.Director |
| Mr. Milind Thatte | Managing Director |
| Mr. Lokesh Chandak | Executive Director & CFO |
| Ms. Seema Sambasivan | Non Executive Director |
| Mr. Aalok Agrawal | Non Executive Director |
| Ms. Krishna Sarma | Independent Director |
| Mr. Sharad Tyagi | Independent Director |
FAQ
What is the intrinsic value of Procter & Gamble Health Ltd?
Procter & Gamble Health Ltd's intrinsic value (as of 26 January 2026) is ₹3562.23 which is 33.98% lower the current market price of ₹5,396.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹8,956 Cr. market cap, FY2025-2026 high/low of ₹6,739/4,904, reserves of ₹603 Cr, and liabilities of ₹894 Cr.
What is the Market Cap of Procter & Gamble Health Ltd?
The Market Cap of Procter & Gamble Health Ltd is 8,956 Cr..
What is the current Stock Price of Procter & Gamble Health Ltd as on 26 January 2026?
The current stock price of Procter & Gamble Health Ltd as on 26 January 2026 is ₹5,396.
What is the High / Low of Procter & Gamble Health Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Procter & Gamble Health Ltd stocks is ₹6,739/4,904.
What is the Stock P/E of Procter & Gamble Health Ltd?
The Stock P/E of Procter & Gamble Health Ltd is 29.2.
What is the Book Value of Procter & Gamble Health Ltd?
The Book Value of Procter & Gamble Health Ltd is 373.
What is the Dividend Yield of Procter & Gamble Health Ltd?
The Dividend Yield of Procter & Gamble Health Ltd is 2.32 %.
What is the ROCE of Procter & Gamble Health Ltd?
The ROCE of Procter & Gamble Health Ltd is 47.8 %.
What is the ROE of Procter & Gamble Health Ltd?
The ROE of Procter & Gamble Health Ltd is 36.4 %.
What is the Face Value of Procter & Gamble Health Ltd?
The Face Value of Procter & Gamble Health Ltd is 10.0.